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Evidence from numerous observational studies
demonstrates that HRT reduces the primary risk of car-
diovascular disease in previously healthy postmenopausal
women.5-7 However, the potential benefit of HRT as sec-
ondary prevention has been questioned. A recent ran-
domized clinical trial documented that hormone therapy
increases the early risk of coronary and thromboembolic
events in women with established cardiovascular disease.8
The effect of HRT on women with established peripheral
vascular disease has not been defined. Successful iliac
angioplasty usually produces a limited arterial dissection
after fracture of the atherosclerotic plaque, and the use of
HRT in women undergoing angioplasty and placement of
a stent into injured endothelium might exacerbate the risk
of thrombus formation.9
In this study we investigated the outcome of women
undergoing iliac artery angioplasty and stent placement
and defined preoperative, procedural, and artery-specific
factors that are predictive of adverse results. The effect of
estrogen replacement therapy on stent patency, in particu-
lar, was analyzed, and the association with an increased
Several observational studies have shown that female
sex is an independent predictor of poor primary patency
after iliac artery angioplasty and iliac artery stenting.1-4
Specific risk factors related to women, such as the effect of
hormone replacement therapy (HRT), have not been con-
sidered because previous studies have compared the results
of treatment in both sexes and the same risk factors have
been evaluated. None of these reports have focused on
women undergoing iliac angioplasty and stenting.
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Influence of hormone replacement therapy on the
outcome of iliac angioplasty and stenting
Carlos H. Timaran, MD, Scott L. Stevens, MD, Oscar H. Grandas, MD, Michael B. Freeman, MD, and
Mitchell H. Goldman, MD, Knoxville, Tenn
Objective: Thromboembolic events are more frequent in women with established cardiovascular disease taking hormone
replacement therapy (HRT). The effect of HRT on the outcome of women with aortoiliac occlusive disease is unknown.
The purpose of this study was to estimate the influence of risk factors, including HRT, on the outcome of women under-
going iliac artery angioplasty and stent placement.
Methods: During a 5-year period (between 1994 and 1999), 126 iliac angioplasties with stent placement (144 stents) were
performed in 88 women. The criteria prepared by the Ad Hoc Committee on Reporting Standards (Society for Vascular
Surgery/International Society for Cardiovascular Surgery) were followed to define the variables. Both univariate (Kaplan-
Meier) and multivariate analyses (Cox proportional hazards model) were used to determine the association among preop-
erative variables, cumulative patency, limb salvage, and survival.
Results: The patients’ average age was 63.2 years with 43% of the patients taking HRT. Indications for iliac angioplasty
with stenting were disabling claudication (65%), limb salvage (32%), and blue toe syndrome (3%). The technical success
rate was 95% (120 of 126 procedures). Primary stenting was performed in 28 patients (22%). Stents were placed selec-
tively after iliac angioplasty for residual stenosis or pressure gradient (57%), iliac dissection (8%), long-segment occlusions
(8%), or eccentric lesions (5%). There were no significant differences between HRT users and nonusers with regard to risk
factors, except there was a higher frequency of diabetes in women taking HRT. Overall, the primary patency rate was 76%
at 1 year, 67% at 3 years, and 62% at 5 years. Primary patency rates at 1, 3, and 5 years were 75%, 57%, and 49% for users
of HRT and 77%, 74%, and 74%, respectively, for nonusers. Limb salvage rates were not statistically different between users
and nonusers of HRT at 5 years (95% vs 96%). Univariate and Cox regression analyses identified HRT use (Kaplan-Meier,
log-rank test, P = .02; relative risk, 2.4; 95% CI, 1.3-4.5; P = .006) and stent placement in the external iliac artery (rela-
tive risk, 4.3; 95% CI, 2.3-7.9; P < .001) as independent predictors of decreased primary patency. 
Conclusions: Women undergoing iliac angioplasty with stent placement who are taking HRT have significantly reduced pri-
mary patency rates. Despite initial technical success, HRT users are at increased risk of long-term failure and might require
subsequent procedures to obtain clinical success. External iliac angioplasty and stenting are also associated with decreased
primary stent patency in women. (J Vasc Surg 2001;33:S85-92.)
risk for thromboembolic events in women with preexisting
cardiovascular disease was recognized.
METHODS
During a 5-year period (June 1994 to June 1999),
126 consecutive iliac angioplasties and stent placement
(144 stents in total) were performed in 88 women at the
University of Tennessee Medical Center at Knoxville, and
all were included in a retrospective cohort study. All the
patients were postmenopausal and had evidence of chronic
limb ischemia. Demographic data, risk factors, complica-
tions, and outcome variables were defined according to
the criteria prepared and revised by the Ad Hoc
Committee on Reporting Standards (Society for Vascular
Surgery/International Society for Cardiovascular Surgery
[SVS/ISCVS]).10,11 Patients who had undergone a previ-
ous iliac angioplasty, stenting, or both were not included.
Preoperative evaluation of all patients included a history
and physical examination, an electrocardiogram, a chest x-
ray film, blood work, noninvasive vascular determination
of ankle-brachial and toe-brachial indices, Doppler scan
wave recordings, arteriogram of the aorta and runoff ves-
sels, and cardiac testing as indicated. The procedures were
performed in the angiography suite by interventional radi-
ologists after consultation with the attending vascular sur-
geon or in the operating room by vascular surgeons.
Arteriography was performed by means of an ipsilateral or
contralateral femoral approach. Bilateral femoral approach
was used frequently for patients who required bilateral
stent placement. Stents were placed through 7F or 8F
sheaths. A balloon-expandable Palmaz stent (Cordis J and
J, Warren, NJ) was used preferentially for focal lesions, for
severely calcified lesions, and for all lesions adjacent to the
aortic bifurcation. A self-expandable Wallstent (Boston
Scientific Vascular, Boston, Mass) was usually placed for
long-segment disease or tortuous iliac arteries and for con-
tralateral approaches. A combination of the two stents was
generally used to provide extra length if the lesion could
not be completely covered by a Wallstent. Heparin was
given systemically before stent placement. Papaverine was
used selectively to treat arterial spasm. Variables analyzed
included age, indication for the procedure and extent of
ischemia, comorbidities (diabetes mellitus, hypertension,
hyperlipidemia, coronary artery disease, cerebrovascular
disease, end-stage renal disease, smoking history), use of
HRT, runoff score, nature of the lesion (stenosis or occlu-
sion), degree of initial arterial stenosis, maximum balloon
size used for dilatation, type of stent (Wallstent vs
Palmaz), maximum number of stents used per limb,
degree of residual stenosis, patency of the ipsilateral super-
ficial femoral artery (SFA) and profunda femoris artery,
patency of tibial arteries, and location of the lesion (com-
mon iliac artery [CIA] vs external iliac artery [EIA]). The
American Heart Association (AHA) classification of dis-
ease severity for peripheral endovascular procedures was
used to define the categories of the lesions.12 Runoff was
classified from review of both preoperative and intraoper-
ative arteriograms (Ad Hoc Committee on Reporting
standards, SVS/ISCVS).10 Runoff was assessed in the
common femoral artery, the SFA, and the deep femoral
artery. The angiographic runoff score was further used for
subgroup analysis; scores were categorized as poor runoff
(score ≥ 5) and good runoff (score < 5). Infrainguinal
bypass graft procedures performed within 30 days of stent
placement were considered “concomitant procedures” to
improve distal runoff.
HRT was defined as the long-term use of standard-
dose estrogen, equivalent to 0.625 mg of conjugated
equine estrogen daily, or the long-term use of standard-
dose estrogen plus a progestin. Neither patients taking
oral contraceptives nor patients using selective estrogen
receptors modulators, such as tamoxifen, were included in
the study. HRT use was assessed by questioning the
patients at each follow-up visit. However, hormone levels
were not measured.
Preoperative, intraoperative, and follow-up informa-
tion was available in all patients and was obtained through
office and hospital chart review, dictated operative
records, and telephone conversations with patients, physi-
cians, or family members. The study protocol was
approved by the local institutional review board. Stent
placement was deemed technically successful if there was
less than a 30% residual stenosis and if the gradient across
the treated lesion was less than 5 mm Hg. There was no
strict postoperative surveillance protocol. However, the
patients were usually seen within 2 weeks from the time of
the procedure. Improvement and changes in clinical status
were determined with the patients’ history and noninva-
sive vascular laboratory tests. At the discretion of the
attending surgeon, postoperative follow-up (clinical and
serial duplex ultrasound scanning examinations) was con-
ducted every 3 months during the first postoperative year
and every 6 months thereafter. Arteriography was per-
formed when duplex scanning revealed a decrease in the
ankle-brachial index of 0.15 or more or if peak systolic
velocities were greater than 300 cm/s. Indications for
reintervention included a stenosis greater than 60% and a
gradient across the lesion greater than 15 mm Hg with
papaverine or greater than 10 mm Hg at rest. All revisions
performed based on these criteria or occlusion were con-
sidered a stent failure and an end of primary patency.10
Survival could be established by telephone contact, but
iliac stent patency and limb salvage were determined at the
date of the most recent examination. 
On the basis of prior reports and for sample size cal-
culations, enrollment of patients undergoing a minimum
of 124 procedures, 31 in the HRT group and 93 in the
non-HRT group, with a two-sided Type I error rate of
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0.05, would be necessary to obtain at least 80% power to
detect a decrease in the 5-year primary patency rate, from
70% in non-HRT users to 35% in HRT users (relative risk
[RR], 2).1-4,13-15 Our sample size was defined during the
study design and was large enough to fulfill such an esti-
mation.
Demographic data and risk factors were compared
between HRT users and nonusers. Continuous variables
were analyzed with the Student t test, and univariate
analysis of categorical variables was performed with the
Fisher exact test or χ2 with Yates correction, as indicated
(χ2 for contingency tables, 2-tailed P value). All analyses
were performed according to the intention-to-treat princi-
ple. Primary angioplasty and stent patency, limb salvage,
and patient survival were determined with the Kaplan-
Meier method.16 The log-rank test (Mantel) was used to
define statistical differences for each variable between the
subgroups. To avoid double counting of cumulative sur-
vival events in patients who underwent multiple index
procedures, we only included follow-up times of survival
for the first procedure. The influence of various risk factors
on stent patency, limb salvage, and patient survival was
assessed with multivariate analysis with Cox proportional
hazards model, which adjusts for the correlation among
multiple observations per patient. Variables that had a P
value less than .25 in the univariate analysis and those
known to be important or possible confounding factors
were entered into the regression model and considered
significant by forward stepwise selection if P was less than
.05 in the final regression equation. By this method, the
RR and 95% CI for the different variables were also esti-
mated, validating the statistical differences from a clinical
and epidemiologic standpoint.17,18 For statistical analyses,
SPSS for Windows version 9.0 (SPSS Inc, Chicago, Ill)
was used.19
RESULTS
The average age of the 106 patients was 63.2 years
(range, 41-89 years). The mean follow-up period was 28.4
months (range, 3-67 months). The most commonly asso-
ciated risk factors in the overall group were a significant
history of tobacco use (86%), hypertension (76%), hyper-
lipidemia (75%), coronary artery disease (65%), and dia-
betes mellitus (35%). Other risk factors included a history
of chronic obstructive pulmonary disease (35%), cere-
brovascular disease (32%), and end-stage renal disease
(4%). Indications for revascularization were disabling clau-
dication in 82 procedures (65%), limb salvage in 40 (32%;
ischemic rest pain in 20 [16%]; tissue loss in 20 [16%]),
and blue toe syndrome in 4 (3%). The mean preoperative
ankle-brachial index at rest was 0.62 ± 0.24.
Most procedures were performed percutaneously
(91%) with patients under local anesthesia (79%). Ninety-
six procedures were performed in the angiography suite
and 30 in the operating room. Eighty-six procedures were
performed by an interventional radiologist, 30 by a vascu-
lar surgeon, and 10 by both. Primary stenting was per-
formed in 28 patients (22%). Selective stenting was
performed in the following indications: a residual stenosis
or pressure gradient after angioplasty (57%), a dissection
after balloon angioplasty (8%), a long-segment occlusion
(8%), or an eccentric lesion (5%). Stents were placed in 76
category 1 or 2 lesions (60%) and in 50 (40%) category 3
or 4 lesions. Palmaz stents were used in 67 procedures
(53%), Wallstents in 51 (40%), and a combination of both
in 8 (7%). Single stents were used in 66 lesions (52%), two
stents in 38 (40%), and three stents in 2 (2%).
Initial technical success was obtained in 120 procedures
(95%). Sixteen patients (18%) underwent an additional con-
comitant surgical procedure: 10 femoropopliteal bypass
grafts, 2 femorofemoral bypass grafts, and 2 SFA angioplas-
ties. Local complications included two hematomas of the
groin treated conservatively. There were 12 vascular com-
plications: 10 arterial dissections and 2 femoral pseudo-
aneurysms. Three dissections required surgical intervention,
as did one pseudoaneurysm; all of these patients underwent
aortobifemoral bypass grafting and were considered stent
failures. Neither stent infection nor distal embolization
occurred. Eighteen patients underwent a surgical recon-
struction (16 aortobifemoral and 2 femorofemoral bypass
grafts) at a mean of 7.0 months after iliac angioplasty and
stenting.
Thirty-eight patients (43%) were taking HRT preoper-
atively. None of the patients either discontinued or started
HRT during the follow-up period. Twenty-eight patients
(32%) were receiving only estrogen therapy, whereas 10
patients (11%) were receiving combined therapy with
estrogen and progestin. Users of HRT had a significantly
higher frequency of diabetes compared with nonusers (53%
vs 28%; P = 0.03), with no other significant differences
noted with univariate analysis with regard to patient risk
factors (Table I). The frequency and distribution of the
characteristics of the iliac lesions were not significantly dif-
ferent between HRT users and nonusers, except that none
of the patients in the HRT group had a category 1 lesion
(Table II). Degree of initial arterial stenosis, maximum bal-
loon size used for dilatation, maximum number of stents
used per limb, patency of the ipsilateral SFA and profunda
femoris artery, patency of tibial arteries, and runoff scores
were not significantly different between HRT users and
nonusers. The number of angioplasty procedures per
patient was similar between users and nonusers of HRT
(1.36 vs 1.48, respectively; P = .89). Incidence and type of
complications were not appreciably different between the
groups (P > .05). The need for an additional distal bypass
graft procedure was not significantly different either (P =
.25); four of 16 patients who required additional bypass
graft procedures were receiving HRT.
Primary patency rates for all women at 1, 3, and 5
years were 76%, 67%, and 62%, respectively. Primary
patency rates for HRT users at 1, 3, and 5 years were
74%, 57%, and 49%, respectively (see appendixes I and II
online). Primary patency rates for HRT nonusers at 1, 3,
and 5 years were 77%, 74%, and 74%, respectively. Users
of HRT had a significant decreased primary patency with
respect to nonusers with univariate analysis (Fig 1;
Kaplan-Meier, log-rank test, P = .02). Women who had
EIA stents placed also had statistically significant
decreased primary patency rates (Kaplan-Meier, log-rank
test, P < .001), compared with the patients who had CIA
stents. Primary patency rates for women who had EIA
stents at 1, 3, and 5 years were 55%, 43%, and 22%, and
for women with CIA stents they were 83%, 77%, and
77%, respectively (Fig 2). Primary patency rates were not
significantly different for the other variables analyzed.
Primary patency rates for diabetic patients at 1, 3, and 5
years were 72%, 64%, and 64%, respectively. Primary
patency rates for nondiabetic patients at 1, 3, and 5 years
were 77%, 67%, and 64%, respectively. There was no sig-
nificant difference in primary patency rates between dia-
betic and nondiabetic patients (Kaplan-Meier, log-rank
test, P = .88). Primary patency rates for smokers and non-
smokers were also compared, and there was no significant
difference (Kaplan-Meier, log-rank test, P = .32). There
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Table I. Patient characteristics of HRT users and nonusers
Users of HRT (%) Nonusers of HRT (%)
(n = 38) (n = 50) P value
Mean age (y) 60.9 63.8 NS
Comorbidities
Diabetes mellitus 20 (53) 14 (28) .03*
Hypertension 30 (79) 36 (72) NS
Tobacco abuse 32 (84) 40 (80) NS
Coronary artery disease 22 (58) 34 (68) NS
Renal insufficiency (creatinine level > 1.6) 4 (10) 10 (20) NS
Previous vascular reconstruction 5 (15) 12 (12) NS
Indications
Claudication 24 (63) 32 (64) NS
Rest pain 6 (16) 8 (16) NS
Tissue loss 8 (21) 8 (16) NS
*χ2 Analysis.
HRT, Hormone replacement therapy; NS, not significant.
Table II. Distribution, characteristics, and procedural factors of 126 iliac angioplasty and stenting  procedures compar-
ing HRT users and nonusers
Users of HRT (%) Nonusers of HRT (%)
(n = 52) (n = 74) P value
Vessel size (mm)* 7.2 ± 0.8 7.1 ± 1.5 NS
Artery treated
CIA 38 (73) 48 (65) NS
EIA 2 (4) 6 (8) NS
Both 12 (23) 20 (27) NS
Iliac disease
Stenosis 46 (89) 70 (95) NS
Occlusion 6 (11) 4 (5) NS
Category/disease severity (AHA grading)
1 0 (0) 8 (11) .02†
2 26 (50) 42 (57) NS
3 18 (35) 14 (19) NS
4 8 (15) 10 (14) NS
Poor runoff (score > 5) 10 (19) 16 (22) NS
Stent type
Palmaz (balloon-expandable) 26 (50) 41 (55) NS
Wallstent (self-expandable) 23 (44) 28 (38) NS
Both 3 (6) 5 (7) NS
*Maximum balloon size used for dilatation; mean ± SD.
†Fisher exact test.
AHA, American Heart Association; CIA, common iliac artery; EIA, external iliac artery; HRT, hormone replacement therapy; NS, not
significant.
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was a trend of decreased primary patency rates among
patients with a history of hyperlipidemia; however, this
trend did not achieve statistical significance (Kaplan-
Meier, log-rank test, P = .06). In addition, primary
patency rates were not significantly different as to the type
of the lesion (stenosis or occlusion), disease severity (cate-
gories of the lesions), types of stent used, vessel size (max-
imum balloon size used for dilatation), runoff scores, and
patency of the ipsilateral SFA. Cox regression analysis
revealed that HRT use (RR, 2.4; 95% CI, 1.3-4.5; P =
.006) and stent placement in the EIA (RR, 4.3; 95% CI,
2.3-7.9; P < .001) were the only independent predictors
of decreased primary patency when controlling for the
presence of all other risk factors. Exclusion of users of
combined estrogen and progestin therapy from the analy-
ses did not change the results; the risk of reduced primary
patency was also significantly increased in women taking
only estrogen therapy (Table III).
Stratified univariate and multivariate analyses includ-
ing only the less severe lesions (ie, categories 1 and 2)
revealed similar results; users of HRT had a significant
decreased primary patency with respect to nonusers with
univariate analysis (Kaplan-Meier, log-rank test, P = .003).
Primary patency rates at 1, 3, and 5 years were 77%, 61%,
and 46% for HRT users and 87%, 83%, and 83%, respec-
tively, for nonusers. HRT use was also identified as the
only independent predictor of decreased primary patency
(RR, 3.4; 95% CI, 1.4-8.1; P = .006). Stratified analyses
also revealed that exclusion of those patients who required
additional distal bypass graft procedures did not affect the
results; HRT was again an independent predictor of
decreased primary patency with multivariate analysis (RR,
3.5; 95% CI, 1.7-7.1; P = .001). Finally, exclusion of
patients who underwent multiple angioplasty and stenting
procedures did not change the results; HRT use was asso-
ciated with a reduced primary stent patency (RR, 3.0; 95%
CI, 1.2-7.8; P = .002).
For all women, limb salvage at 1, 3, and 5 years was
98%, 96%, and 96%, respectively. Limb salvage analyses
with Kaplan-Meier and log-rank test revealed no significant
differences with HRT use. With univariate and multivariate
analyses, history of renal disease (creatinine level > 1.6
mg/dL) was identified as the only independent predictor
of reduced limb salvage (Table III). No operative (30-day)
deaths occurred. Overall, long-term survival was 95% at 1
year, 93% at 3 years, and 89% at 5 years. Cumulative patient
survival was not statistically different between HRT users
and nonusers (Kaplan-Meier, log-rank test, P = .78).
Diabetes mellitus was the only independent predictor of
decreased long-term survival with multivariate analysis
(RR, 5.3; 95% CI, 1.2-26.4; P = .04; Table III).
DISCUSSION
This study indicates that HRT use is an important fac-
tor contributing to decreased primary patency rates after
iliac angioplasty and stent placement in women. Female
sex was found in previous studies to be a risk factor for
lower patency rates after iliac artery angioplasty and stent-
ing. However, specific risk factors related to women, such
as the use of HRT, have not been analyzed.1-4 In series
Fig 1. Primary patency rates after iliac artery angioplasty and stenting were significantly lower in HRT users compared with nonusers
(Kaplan-Meier, log-rank test, P = .02). HRT, Hormone replacement therapy.
with iliac angioplasty alone, stratified analyses and evalua-
tion of subgroups of patients have also revealed evident
differences between the two sexes. In the subanalysis of
external iliac stenosis, Johnston1 found a lower patency
rate for women than for men. Smaller vessel size has been
suggested as a possible reason for decreased patency rates
in females, but this assumption has also been questioned
in the literature because of inconsistent results.20 In previ-
ous studies etiology for iliac stent failure in women has not
been identified. 
Prospective and retrospective observational studies
have demonstrated that HRT reduces the primary risk of
coronary artery disease in healthy postmenopausal
women.5-7 The influence of HRT in women with cardio-
vascular disease, however, is not well defined. The Heart
and Estrogen/Progestin Replacement Study, the first ran-
domized clinical trial to analyze the effect of estrogens
plus medroxyprogesterone in postmenopausal women
with established cardiovascular disease, revealed that HRT
was associated with an early increased risk of thromboem-
bolic and coronary events. These authors recommend not
starting HRT as secondary prevention of coronary heart
disease.8 The exact mechanism of increased risk for coro-
nary events is unknown. The effects of estrogens, pro-
gestin, or both on nonvascular tissues, such as the liver,
may cause a prothrombotic and proischemic state with an
altered coagulation profile.21,22 These effects may out-
weigh the proposed favorable influence of estrogens on
lipoproteins, atherosclerosis, and endothelial function.6
Additional evidence of the effect of postmenopausal hor-
mones on risk of thrombosis has been reported. Three
large epidemiologic studies independently found that cur-
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Table III. Independent predictors of iliac stent patency, limb salvage, and cumulative survival*
Coefficient RR† 95% CI P value
Primary patency
HRT 0.874 2.4 1.3-4.7 .006
HRT with estrogen only 1.269 3.6 1.9-6.6 .001
Stent location (EIA) 1.451 4.2 2.3-7.9 .001
Limb salvage
Renal insufficiency (creatinine level > 1.6) 2.651 9.8 2.5-7.7 .002
Cumulative survival
Diabetes 1.672 5.3 1.2-26.4 .041
*Variables with a P value < .25 with the univariate analysis were entered into the multivariate Cox regression models and selected by for-
ward stepwise selection if P value < .05 (P < .001 for models).
†RR of adverse outcome (ie, decreased patency, limb salvage, and survival) for each predictor.
EIA, External iliac artery; HRT, hormone replacement therapy; RR, relative risk.
Fig 2. Primary patency rates were significantly lower in women who underwent EIA angioplasty and stenting with regard to those who
had CIA stents (Kaplan-Meier, log-rank test, P < .001).
rent users of HRT had a twofold to threefold increase in
risk for both deep venous thrombosis and pulmonary
embolism.23-25 The risk was highest in the first few years
of use, and risk was increased for use of both estrogen
alone and estrogen plus progestin. Some studies report
rises in clotting factor concentrations, whereas others indi-
cate no in vitro coagulability changes among HRT
users.6,21,22 In a previous study from our institution, HRT
use was identified as the only independent predictor of
reduced primary graft patency after femoropopliteal
bypass graft procedures in women.26
In our series, multivariate analyses identified HRT use,
including estrogen plus progestin or estrogen alone, as an
independent predictor of decreased primary patency. An
increased risk of thromboembolic events in patients taking
HRT may account for this adverse outcome. The reduced
primary patency rates in women taking HRT who
undergo iliac angioplasty with the addition of stents may
indicate an adverse association of two thrombogenic fac-
tors. Placement of a stent into injured endothelium or
exposed collagen increases the risk of thrombus forma-
tion.9 Stents also generate myointimal hyperplasia and
subsequent restenosis or occlusion.27 In this series, most
of the patients underwent selective stenting (ie, stents
were placed for unsatisfactory or complicated iliac angio-
plasty). In this setting, HRT use may exacerbate the risk of
intra-arterial thromboembolic events. Stratified analyses to
determine the influence of HRT use in women undergo-
ing primary iliac stenting was subject to a Type II statisti-
cal error because of the small number of patients and
could not be performed. However, as reported in previous
studies, in the current series women undergoing system-
atic primary stenting did not have significantly different
primary patency rates when compared with those who had
selective stent placement (Kaplan-Meier, log rank, P =
0.65).28,29
Stratified analyses including only AHA category 1 or 2
lesions, the ones considered the most favorable for
endovascular procedures, revealed similar results; HRT
was the only independent predictor of decreased primary
patency. For this subgroup of patients, anatomic location
(CIA vs EIA) was not found to influence iliac stent
patency.
This study does adhere to the current criteria prepared
and revised by the Ad Hoc Committee on Reporting
Standards (SVS/ISCVS).10,11 However, an overestima-
tion of the influence of risk factors particular to those
patients who underwent more than one procedure could
be possible when basing the different analyses on the
number of lesions and procedures. Stratified analysis
including only the first procedure performed in each
patient (ie, considering the patient as the unit of study)
has been suggested as a method to avoid this overestima-
tion of risk factors. Because most patients who had more
than one procedure underwent the second procedure
simultaneously (bilateral iliac angioplasty and stenting),
such stratified analyses could not be performed.
Stratified analyses excluding those patients who under-
went additional distal bypass graft procedures and those
who had undergone multiple angioplasty and stenting
procedures were obtained to avoid a possible bias, and
these calculations revealed similar results: HRT was again
an independent predictor for decreased primary stent
patency.
Women using HRT had a higher frequency of dia-
betes. This risk factor, however, failed to explain the
adverse outcome of HRT users because it was neither a
statistically significant factor with univariate analysis nor an
independent predictor with multivariate analysis of
decreased primary patency.
Renal insufficiency was the only independent risk fac-
tor for decreased limb salvage, whereas diabetes was the
only independent predictor of decreased survival. HRT
use was not associated either to decreased limb salvage or
patient survival.
The lack of randomization and potential bias in patient
selection are limitations of any observational study. In our
study, different variables, including the patterns of use of
HRT, and the various outcomes were evaluated in a clinical
setting. Our data indicate a decrease in primary patency
associated with HRT use after iliac angioplasty and stenting.
These observations suggest the need for further studies to
investigate the significance of HRT for reconstructions at
other vascular sites and to elucidate mechanisms of HRT-
mediated stent failure. Anticoagulation, particularly, should
be investigated as a factor to improve the patency rate for
these patients at high risk for stent failure.
CONCLUSIONS
Women undergoing iliac angioplasty and stent place-
ment who are taking HRT have a significantly reduced
primary patency. Despite initial technical success, HRT
users are at increased risk of long-term failure and might
require subsequent procedures to obtain clinical success.
External iliac angioplasty and stenting is also associated to
decreased primary stent patency in women.
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